Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/IIa Clinical Trial on the Safety and Preliminary Efficacy of Donor-derived Anti-leukemia Cytotoxic T Lymphocytes for the Prevention of Leukemia Relapse in Children Given Haploidentical Hematopoietic Stem Cell Transplantation

NCT06865352 is registered in ClinicalTrials.gov with Fondazione IRCCS Policlinico San Matteo di Pavia as lead sponsor.

NCT NCT06865352
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06865352 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/IIa Clinical Trial on the Safety and Preliminary Efficacy of Donor-derived Anti-leukemia Cytotoxic T Lymphocytes for the Prevention of Leukemia Relapse in Children Given Haploidentical Hematopoietic Stem Cell Transplantation
Lead sponsor
Fondazione IRCCS Policlinico San Matteo di Pavia
Phase
Phase 1/2
Overall status
Completed
Start date
February 13, 2021
Completion date
January 30, 2025
Enrollment
15 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia all, acute myeloid leukemia (aml)